Latest Cash Runway News

Evolution Energy Minerals has ramped up exploration at its Chikundo Copper Project while stabilising its finances and navigating regulatory hurdles in Tanzania. The company is preparing for drilling in 2026 despite a tight cash position.

Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.

Avenira Limited has made significant strides in developing its Wonarah Phosphate Project, bolstered by strategic operational appointments and advancing infrastructure plans. Meanwhile, exploration at the Jundee South Gold Project is set to commence in 2026 amid ongoing regulatory challenges.

NT Minerals Limited reported a mixed cash flow quarter ending December 2025, with ongoing operational losses offset by strong investing inflows and a solid funding buffer. The company signals confidence in continuing operations despite tight liquidity.

Immutep Limited has entered a strategic collaboration with Dr. Reddy’s, receiving a A$30 million upfront payment and potential milestones up to A$528 million, while reporting promising clinical progress across multiple cancer immunotherapy trials.

FBR Limited has set a new speed record with its Hadrian H04 bricklaying robot and secured its first binding sale of the Mantis welding robot, while advancing its partnership with Samsung Heavy Industries and navigating tight cash reserves.

Freedom Care Group Holdings reports a modest cash increase to $0.5 million but continues to grapple with delayed payments from the NDIA, while exploring options to relist on the ASX.

Verity Resources has delivered strong drilling results at its Monument Gold Project, secured full ownership of Botswana copper-silver assets, and confirmed significant rare earth mineralisation in Brazil, setting the stage for a pivotal 2026.

Cynata Therapeutics has completed enrolment in major clinical trials for osteoarthritis and acute graft versus host disease, with pivotal results expected in the second quarter of 2026. The company also strengthened its patent portfolio and secured additional funding to extend its operational runway.

Racura Oncology reported a transformative quarter with key scientific discoveries, expanded clinical programs, and a robust cash position of $20.94 million, setting the stage for pivotal cancer trials in 2026.

Diablo Resources reported a net cash outflow of A$456k for operating activities in the December 2025 quarter, offset partially by a A$2 million equity raise. Despite this, the company’s cash runway remains limited to about one quarter, prompting plans for further funding.

Lefroy Exploration Limited reported a net cash outflow in operating and investing activities for Q4 2025, balanced by financing inflows, leaving it with $1.85 million in cash and a funding runway of just over two quarters.